Self-assembling drugs: A new approach to biochemical modulation in cancer chemotherapy

Cancer Investigation

Volumn 12, Issue 2, 1994, Pages 189-202

  Rideout, Darryl ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHELATING AGENT; NEW DRUG; PLATINUM DERIVATIVE;

CANCER; CANCER CHEMOTHERAPY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; HYDRAZONES; PRODRUGS; PROTEIN KINASE C; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028288945     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909409024874     Document Type: Article

References (86)

1. Clinical studies of combination chemotherapy for cancer
2. Synergism and antagonism in cancer chemotherapy
3. Synergism. antagonism. and potentiation in chemotherapy: An overview
4. Self-assembling cytotoxins
5. Synergism and antagonism through direct bond formation between two agents in situ
6. Synergism through direct covalent bonding between agents: A strategy for rational design of chemotherapeutic combinations
7. A self-assembling protein kinase C inhibitor
8. Inhibition of putrescine uptake by polypyridinium quaternary salts in B16 melanoma cells treated with difluoromethylornithine
9. 1H NMR
10. Interactions between DNA and mono-, bis-, tris-, tetrakis-, and hexakis(aminoacridines). A linear and circular dichroism, electric orientation relaxation, vis-cometry. and equilibrium study
11. DNA tris-intercalation: First acridine trimer with DNA affinity in the range of DNA regulatory proteins. Kinetic studies
12. New dimeric analogues of ethidium: Synthesis interaction with DNA and antitumor activity
13. Chemistry of antiturnor drugs
14. Activity of platinum (II) intercalating agents against murine leukemia L1210
15. Selective DNA interaction of the novel distamycin derivative FCE 24517
16. Antimitotic agents: Synthesis of imidazo[4,5-clpyridin-6-ylcarbamates and imidazo[4,5-bipyridin-5-ylcarbamates
17. Antitumor and radiosensitizing activity of several platinum-(+) dye complexes
18. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation
19. Platinum-amine compounds: Importance of the labile and inert ligands for their pharmacological activities toward L1210 leukemia cells
20. Platinum drug delivery through ion pair formation in vivo
21. Intracellular distribution of a platinum-rhodamine 123 complex in cis-platinum sensitive and resistant human squamous carcinoma cell lines
22. High-performance liquid chromatographic studies of reaction of hydralazine with biogenic aldehydes and ketones
23. New aspects of the Maillard reaction in foods and in the human body
24. Several inhibitors of ornithine and adenosylmethionine decarboxylases may also have antiproliferative effects unrelated to polyamine depletion
25. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer
26. Placebo-controlled double-blind comparative study on the preventative efficacy of mesna against ifosfamide-induced urinary disorders
27. High-dose ifosfamide with mesna uroprotection: A phase I study
28. Chloracetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication
29. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: A Gynecologic Oncology Group study
30. lfosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease
31. vitrolin vivo effects of mesna on the genotoxicity and toxicity of cyclophosphamide—a study aimed at clarifying the mechanism of mesna's anticarcinogenic activity
32. Purification and characterization of aclacinomycin A and its metabolites from human urine
33. Plasma kinetics of aclacinomycin A and its major metabolites in man
34. vitro and in vivo evidence for the formation of methyl radical from procarbazine: A spin-trapping study
35. A cytochemical method for selective intracellular damage with a ruby laser
36. A cytochemical approach to the laser coagulation of the ciliary body
37. Interaction of cisplatin and carboplatin with sodium thiosulfate: Reaction rates and protein binding
38. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles
39. lntraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection
40. The effect of sodium thiosulfate on sub-cellular localization of platinum in rat kidney after treatment with cisplatin
41. Effect of sodium thiosulfate on the pharmacolinetics and toxicity of cisplatin
42. Effects of cisplatin and thiosulfate upon auditory brainstem responses of guinea pigs
43. Nephrotoxicity and carcinogenic risk of cisplatin (CDDP) prevented by sodium 2-mercaptoethane-sulfonate (mesna): Experimental results
44. Effects of diethyldithiocarbamate and nine other nucleophile on the intersubunit protein cross-linking and inactivation of purified human macro-globulin by cis-diamminedichloroplatinum (II)
45. Diethyldithiocarbamate modulation of marrow toxicity induced by cis-diammine(cyclobutanedicar-boxylato)platinum (II)
46. Whither the modulation of platinum
47. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin
48. Agent designed for war now in doctor's armamentarium
49. Possible catalytic activity of DNA in the reaction between the antitumor drug cis-diamminedichloroplatinum (II) and the intercalator N-methyl-2, 7-diazapyrenium
50. Reaction of nucleic acids and cis-diamminedichloroplatinum (II) in the presence of intercalating agents
51. Characterization of the ternary complexes formed in the reaction of cis-diamminedichloroplatinum (II). ethidium bromide and nucleic acids
52. DNA promotes the reaction of ris-diamminedichloroplatinum (II) with the exocyclic amino groups of ethidium bromide
53. Phase I and I agents in cancer therapy: Two cisplatin analogues and high-dose cisplatin in hypertonic saline or with thisolfate protection
54. Reaction of platinum(II) antihumor agents with sulf-hydral compounds and implications for nephrotoxicity
55. Binding kinetics of tetrachloro-1,1-diaminocyclohexaneplatinum (IV) (tetraplatin) and cis-diamminedichloroplatinum (II) at 37°C with human plasma proteins and with bovine serum albumin. Does aquation precede protein binding
56. Antirheurnatics: Penicillamine
57. Activities and regeneration of mouse skeletal muscles after exercise injuries
58. Therapy of P388 leukemia with benzalde-hyde
59. Antitumor activity of a benzaldehyde derivative
60. Effects of N-substitution on the activation mechanisms of 4-hydroxycyclophosphamide analogues
61. Relationship between structure and antineoplastic activity of (arylsulfonyl) hydrazaones of 4-pyridinecarboxaldehyde
62. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers
63. Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes
64. Potential antitumor agents. 31. Quantitative structure-activity relationships for the antileukemic bis-(guanylhydrazones)
65. Receptor-based drug design
66. Environment-selective synergism using self-assembling cytotoxic and antimicrobial agents
67. New S-Adenosylmethionine decarboxylase inhibitors with potent antitumor activity
68. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27
69. Synthesis and antitumor activity of 3– and 5-hydroxy-4-methylpyridine-2-carboxaldehyde thiosemicarbazones
70. The molecular heterogeneity of protein kinase C and its implications for cellular regulation
71. Biochemical characterization of rat brain protein kinase C isozymes
72. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity
73. Inhibition of rodent protein kinase C by the anticarcinoma agent dequalinium
74. Inhibition of experimental metastasis and cell adhesion of B16F1 melanoma cells by inhibitors of protein kinase C
75. Drug delivery through condensation of two prodrugs inside tumor cells: Direct observation using fluorescence microscopy
76. Double-stranded DNA promotes intercalator assembly from an aldehyde and an acylhydrazide
77. Mitochondrial membrane potential in living cells
78. Mitochondria as a reservoir for anticarcinoma
79. Phosphonium salts exhibiting selective anticarcinoma activity in vitro
80. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells
81. Novel stable bioactivated cyclophosphamide derivatives for selective cancer chemotherapy, synthesis of aldophosphamide acetal-glycosides and their glyconjugates
82. Are cancer cells acidic
83. Acid pH in tumors and its potential for therapeutic exploitation
84. A chloroquine-resitant Swiss 3T3 cell line with a defect in late endocytic acidification
85. Diethyldithiocarbamate (DEDC) enhances quinone mediated oxidative stress cytotoxicity in isolated hepatocytes by forming toxic quinone conjugates